ZYME

Zymeworks Inc. (NASDAQ:ZYME) is a clinical-stage biopharmaceutical company founded in 2003 and headquartered in Vancouver, Canada. The company went public in April 2017 and has established itself as a developer of innovative cancer treatments using proprietary antibody engineering platforms. Zymeworks focuses on creating bispecific antibodies and antibody-drug conjugates (ADCs) designed to target multiple pathways simultaneously for enhanced therapeutic efficacy. The company has built a robust pipeline of oncology treatments and has successfully partnered with major pharmaceutical companies including Jazz Pharmaceuticals, BeiGene, GSK, and others to advance its lead programs through clinical development.